On Oct. 18, Boston Scientific (NYSE:BSX) released Q3 earnings for the period ended Sept. 30.

  • Revenues exceeded estimates by $7 million, while earnings missed estimates by $0.04 per share.
  • Revenue rose a robust 34.1%, to $2.02 billion.
  • EPS increased to $0.05, as net income rose to $76 million.
  • Long-term debt increased to $8.89 billion from a year-ago $2.43 billion.

(Figures in millions, except per-share data)

Income Statement Highlights

Avg. Est.

Q3 2006

Q3 2005

Change

Sales

$2,019

$2,026

$1,511

34.1%

Net Profit

--

$76

($269)

N/A

EPS

$0.09

$0.05

($0.33)

N/A

Diluted Shares

--

1,487

820

81.3%



Get back to basics with a look at the income statement.

Margin Checkup

Q3 2006

Q3 2005

Change*

Gross Margin

68.90%

77.30%

(8.40)

Operating Margin

9.62%

(22.24%)

31.86

Net Margin

3.75%

(17.80%)

21.55

*Expressed in percentage points.

Margins are the earnings engine. See how they work.

Balance Sheet Highlights

Assets

Q3 2006

Q3 2005

Change

Cash + ST Invest.

$1,541

$917

68.1%

Accounts Rec.

$1,460

$976

49.6%

Inventory

$759

$410

85.1%


Liabilities

Q3 2006

Q3 2005

Change

Accounts Payable

$1,815

$958

89.5%

Long-Term Debt

$8,893

$1,518

486.8%



Learn the ways of the balance sheet.

Cash Flow Highlights

Boston Scientific did not provide a cash flow statement. (For shame.)

Find out why Fools always follow the money.

Related Companies:

  • Medtronic (NYSE:MDT)
  • St. Jude Medical (NYSE:STJ)
  • Baxter International (NYSE:BAX)

Related Foolishness:

Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.